As a fixed-dose combination, CagriSema was assessed in two phase 3 studies (REDEFINE 1 and 2), resulting in significant and clinically relevant reductions in body weight compared with placebo in adults with overweight or obesity, with [8] or without type 2 diabetes [9]
Oral GLP-1s (Rybelsus and Beyond) Until recently, Rybelsus (manufactured by Novo Nordisk) was the only oral medication in its class with FDA approval
At room temperature and physiological pH, unmodified small peptides in solution degrade over days to weeks, not months
For example, DAMPs such as HMGB1, S100A8/A9, cfDNA, and oxidized low-density lipoprotein (oxLDL) can interact with TLRs, leading to the activation of NF-B and IRF3 pathways through MyD88-dependent or -independent mechanisms